Lawson Research Institute
London, Ontario, N6A 4BQ, Canada
Location contact
Keith St Lawrence, PhD
CONTACT
(519) 646-6100 ext. 65737
Keith St Lawrence, PhD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT06767124
It is projected that by 2030, one in every five Americans will be of retirement age, and this demographic shift is expected to result in more people suffering from dementia. A key feature of the brain is its need for a constant supply of glucose and oxygen to meet the high energy costs of mental activity. This study aims to develop clinically practical, noninvasive imaging methods based on combined positron emission tomography and magnetic resonance imaging to assess brain energy in order to better understand how this critical component of brain health is impacted by aging.
Trial opening soon.
Get Notified21 year and older
All sexes
Interventional
Not applicable
London, Ontario, N6A 4BQ, Canada
Keith St Lawrence, PhD
CONTACT
(519) 646-6100 ext. 65737
Keith St Lawrence, PhD
PRINCIPAL_INVESTIGATOR
There are now close to six million people in the Unites States living with dementia and this number is only expected to grow as the population continues to age. The current lack of effective treatments for Alzheimer's disease (AD) speaks to the need to better understand the multiple factors that contribute to this complex disease. There is growing evidence that age-related metabolic dysfunction in the brain plays a role in the disease's etiology. This concept has led to treatments aimed at improving brain energy production. Notably, ketogenic dietary supplements have been shown to increase brain ketone metabolism and improve cognitive performance in AD patients. However, the overall benefits to brain metabolism in the AD brain are unknown given the complexity of imaging both oxygen and glucose metabolism in a single session by positron emission tomography (PET). Taking advantage of hybrid PET/MR imaging, this study will combine PET and MRI methods to investigate the effects of a ketogenic supplement on brain oxygen and glucose metabolism in AD patients.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy Participants: Males and females, Age 21 - 80 years, BMI of 18.5-30
Inclusion criteria
- Alzheimer's Disease Participants: Positive amyloid and tau biomarkers (as noted by PET imaging, cerebrospinal fluid or blood), Mild cognitive impairment or mild-to-moderate dementia, BMI of 18.5-30
Exclusion criteria
Contraindications to MRI (claustrophobia, metal implants, pacemakers, etc.), Pregnant or breastfeeding women, Neurological disease (healthy participants only), Mental illness, Overt cardio- or neurovascular disease, Recent participation in any procedure(s) involving radioactive agents
Commercially available ketone ester drink
Other names: Ketone-IQTM
Placebo drink containing sunflower oil.
Time frame: CMRO2 will be measured in both imaging sessions (placebo and ketosis)
Statistical analysis of imaging data sets under placebo and ketosis conditions will be used to investigate increases in regional CMRO2 caused by ketosis.
Time frame: CMRGlu will be measued in both imaging session (placebo and ketosis)
Statistical analysis of imaging data sets under palcebo and ketosis conditions will be used to investigate changes in regional CMRGlu caused by ketosis. Unlikek CMRO2, no difference in CMRGlu is expected between the two conditions for Alzheimer's patients.
Time frame: Baseline and 7 Days
A psychometrist will assess baseline cognition using the Mini-Mental State Examination, the Montreal Cognitive Assessment, and the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog). The ADAS-cog will be repeated at the end of the second imaging session to test the potential cognitive benefits of the ketogenic supplement.
Contact information is provided by the study sponsor or research team.
University of Pennsylvania
Other
Simultaneous PET/MR Imaging of Brain Glucose and Oxygen Metabolism to Assess Energy Deficits Related to Alzheimer's Disease and the Response to Intervention
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06860828
Alzheimer Disease, Alzheimer Disease and Related Dementias (ADRD)
Phoenix, Arizona, United States
View Trial DetailsNCT06224205
Alzheimer Disease, Alzheimer Disease and Related Dementias (ADRD)
Boca Raton, Florida, United States
View Trial DetailsNCT06112860
Alzheimer Disease, Alzheimer Disease and Related Dementias (ADRD)
Evanston, Illinois, United States
View Trial DetailsNCT05231954
Alzheimer Disease, Alzheimer Disease and Related Dementias (ADRD)
Indianapolis, Indiana, United States
View Trial Details